Breakthroughs changing
more than 1.3 billion lives
2022 Annual Review
Pzer 2022 Annual Review
2
Contents
A Year in Review
A Letter From Our Chairman & CEO
Partnerships that Change Patients’ Lives
Breakthroughs at Lightspeed
People-Driven Initiatives
2022 Stories
Internal Medicine


Rare Disease
Vaccines
Anti-Infectives
Research & Development
Commercial

COVID-19

Digital
Living Our Values

2022 Progress and Highlights
Performance
Financial Performance
Top 10 Medicines and Vaccines
About This Review

03
04
07
08
09
10
11
13
15
17
18
24
26
29
32
36
40
45
47
48
49
51
52
53
54
55
Pzer 2022 Annual Review
3
A Year in Review
Breakthroughs changing more than 1.3 billion lives
In 2022, we applied the lightspeed principles
that drove the development of our COVID–19
vaccine and treatment to help address unmet
needs across all therapeutic areas. Our
people continued to live our values—courage,

passions and impacting an evolving world.
A Year In Review
ESGA Year In Review 2022 Stories Performance About This Review
Pzer 2022 Annual Review
4
A Letter from Our Chairman & CEO
To Our Shareholders

a new purpose: Breakthroughs that change
patients’ lives
purpose rooted in our commitment to patients,
but we wanted to make our purpose more
memorable, more inspiring and, most important,
more actionable.





of patients for the better. As a result of this
unwavering commitment to innovation and


• 


continue to advance our robust R&D pipeline
of potential breakthrough medicines and
vaccines.
• 
success rates
i
and further improved our


ii
and we did all of this while


• We completed four acquisitions—Arena
Pharmaceuticals, Biohaven Pharmaceuticals,

which have further strengthened both
our pipeline and our current portfolio of

• 


• We exceeded $100 billion in revenues for the

• And, most important, more than 1.3 billion
patients around the world were treated
with our medicines and vaccines.
iii

humbling achievement.
Maintaining Our COVID–19
Leadership

battle against COVID-19. As the virus continued















We are proud to have maintained our leadership
position throughout the public health booster
A Letter From Our Chairman & CEO








source.
i
ii
iii
ESGA Year In Review 2022 Stories Performance About This Review
Pzer 2022 Annual Review


iv


the bivalent booster launch—and our bivalent booster market


proven and reliable manufacturing network, will ensure we are well
positioned to continue to adapt our vaccine as needed and get it to
people around the world.
Our COVID-19 oral treatment, PAXLOVID
®
(nirmatrelvir tablets and


global population at high risk for progressing to severe disease.
v



vi
. As of
March 1, 2023, we have shipped 44 million treatment courses to 63
countries around the world.
Leading the Charge for Equitable Access

breakthroughs get into the hands of those who need them.



determines which of us can access these innovations—and which





countries—with the hope of giving the 1.2 billion people living in
these countries access to hundreds of lifesaving and life-changing

But as we learned in the COVID-19 vaccine rollout, ensuring


health leaders to make improvements in diagnosis, education,





sure our products reach those in need.







A Bright Future for Pzer and for Patients


which we expect to have up to an unprecedented 19 new products
or indications in the market. Fifteen of these 19 are from our

recent business development deals. These potential medicines
and vaccines cut across a range of therapeutic areas and include


ulcerative colitis, and sickle cell disease—among others. This

for patients around the world. This is the promise of our science at
work.

medicines in our pipeline, with numerous launches expected in the
2024-2030 timeframe, if successful in clinical trials and approved.




A Letter From Our Chairman & CEO
CDC data through Jan 4, 2023.



.
iv
v
vi
ESGA Year In Review 2022 Stories Performance About This Review
Pzer 2022 Annual Review
6
Dr. Albert Bourla

Emergency uses of the vaccines have not been approved or licensed by FDA but have been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019
(COVID-19) in individuals aged 6 months and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use
of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.
PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of adults and pediatric patients (12 years of age and older weighing at least 40
kg) with a current diagnosis of mild-to-moderate COVID-19 and who are at high risk for progression to severe COVID-19, including hospitalization or death.
The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products
during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.
We encourage you to read our 2022 Annual Report on Form 10-K, which includes our audited consolidated nancial statements as of and for the year ended December 31, 2022, and the sections
captioned "Risk Factors" and "Forward Looking Information and Factors that May Aect Future Results," for a description of the substantial risks and uncertainties related to the forward-looking
statements included herein. Expected product launches are subject to, among other risks, assumptions and uncertainties, clinical trial, regulatory and commercial success and availability of supply.
A Letter From Our Chairman & CEO




we will continue to leverage business development opportunities


science in the form of both later-stage assets, as well as earlier
medical innovations, that have the potential to be breakthroughs


to add substantial value and select the most successful targets.


and breadth of our portfolio. With the unprecedented wave of

near term, potential business development activities, our increased
investments in our R&D and commercial capabilities, and additional
potential new products and indications coming in the second half
of the decade, we believe we can build on the momentum we have
created to deliver life-changing innovations to even more patients
around the world.

ESGA Year In Review 2022 Stories Performance About This Review
Pzer 2022 Annual Review
Partnerships that Change Patients’ Lives
A Year In Review
Pzer's relationships with academics, biotechs, advocates, and technological revolutionaries help us realize our innovation
goals. Some of our partners:
Global Governments Against Anti-
Microbial Resistance (AMR)




OPKO Health


®
for the

U.S. Government (PAXLOVID
®
)

deliver 20 million PAXLOVID treatment courses in 2022. Outside



Tigerlily

breast cancer—who are at a higher risk of disease—to feel more
educated and supported to participate in clinical trials.
ESGA Year In Review 2022 Stories Performance About This Review
Pzer 2022 Annual Review
Breakthroughs at lightspeed
A Year In Review
Pzer can reach more patients with life-saving treatments, sooner.

in-human to approval development timeline for






After surpassing our existing goals ahead
of schedule, there is no limit to how far we can go in

• 6 Vaccines
• 3
• 6
• 4
We are in the midst of an 18-month period during which we expect to
launch up to an unprecedented 19 new products or indications:
ESGA Year In Review 2022 Stories Performance About This Review
Pzer 2022 Annual Review
9
People-Driven Initiatives
A Year In Review
These passionate Pzer colleagues transformed personal visions into large-scale realities that are positively impacting people
all over the world.





donations arranged and the $30
million committed for humanitarian
support* has and will continue to,




Leadership Initiative Founder

Initiative is not a hand-out. We see
what refugees can bring to the
table, and we welcome their diverse

Zainab Wasti

Experience Lead


Fest, we listened to their stories
and we learned. And we will
continue to do so in order to better

Emma Andrews

"Patients in Focus is a dedicated

around the world, across all our
markets and functions, take time to



distinct legal restrictions.
ESGA Year In Review 2022 Stories Performance About This Review
Pzer 2022 Annual Review
10

Explore some of the most important
breakthroughs from 2022.

a rare disease and women’s health, advancing
treatment for dermatological conditions and


treatment to countries in all regions of the world.
2022 Stories
ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
11

®
(relugolix 40 mg, estradiol 1 mg, and norethindrone
approved

the management of moderate to severe pain associated with
endometriosis in premenopausal women, with a treatment
duration of up to 24 months.
1
data


versus placebo at week 24. Adverse reactions occurring in


disorders, abnormal uterine bleeding, nausea, toothache, back
pain, decreased sexual desire and arousal, arthralgia, fatigue,

2


unmet need in women’s health.





endometriosis associated-pain are not able to manage their

high unmet need for this disease.
It can take between four


and
for some women, current treatment options do not provide
relief.
11
This approval builds on the momentum from 2021’s approval


women, with a treatment duration of up to 24 months. It
also marks an important milestone in our mission to address

treatment options for these conditions, which can be
debilitating.
MYFEMBREE
®

Two Woman’s Health Conditions
Additional indication in endometriosis-associated pain reects Pzer’s
commitment to advancing women’s health.
Internal Medicine
2022 Stories
MYFEMBREE (relugolix, estradiol, and norethindrone acetate) is a once-

for the management of moderate to severe pain associated with
endometriosis, with a treatment duration of up to 24 months.

®

2021. . Accessed October 31, 2022.

®


. Accessed October 31, 2022.
.
Accessed October 31, 2022.








*For full ecacy and safety information about MYFEMBREE, please see the full prescribing information here.
ESG
Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
12

®




ten people living with the condition in Europe alone.
1
The
burden of illness causes a large economic impact, with the

2



from migraine.
3,4
It is a prevalent and disabling illness, and the
















In a prevention trial,


of the 12-week treatment period compared to placebo.
6
The









Migraines for Patients in Europe
The only migraine medication that treats and prevents all in one.
Internal Medicine
2022 Stories



Ashina M. Migraine. N Engl J Med






ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
13

2.6 million people in Europe and an estimated 1 million

1,2
It is a chronic, life-long immune-mediated

of relapse and remission. The disease causes irritation and
ulcers on the inner lining of the large intestine. It is one of a










with IBD.
3





associated with serious AEs.









previous studies of etrasimod. The most common treatment-




were presented as a late-breaker presentation at Digestive
Disease Week (DDW) 2022.
4





patients living with ulcerative colitis might never achieve or







titration scheme to start treatment. Lack of titration combined



critical.



a treat-through trial design, its mechanism of action, and its




need for new therapies. In the ELEVATE clinical program,



Working to Advance Care for People

Etrasimod has the potential, if approved, to be a best-in-class therapy
for moderately-to-severely active UC.
Inammation & Immunology
2022 Stories












ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
14

experiencing something people in their regular social circles







Late one night in college, she was inspired to do something
impactful: share 

awareness. There weren’t online support groups or social



true power of awareness and support.



connected with a group of individuals also living with alopecia










, to help

autoimmune disease.



Areata, I hope to help raise awareness about this disease and





How Two Alopecia Areata Advocates Found

Kylie and Supriya join Pzer’s Reections of Alopecia Areata to share
their stories.
Inammation & Immunology
2022 Stories


ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review



second most common cancer in men and the fourth most
common cancer overall.
1
It is so common that all men are at




continuum.


2
, where the disease is considered curable



disease. It is often then considered incurable. The median
overall survival for patients who have increasing levels of


3
For those

metastatic castration-resistant prostate cancer (mCRPC), the


Research over the past decade has focused on improving
outcomes for men with mCRPC, and while advances have
been made with the introduction of therapies known as novel

resistance and are left with no other treatment options.

breakthrough.

us to explore various therapeutic approaches of potential

Phase 3 TALAPRO-2 trial which found that the combination of

®


®


in radiographic progression-free survival compared with



observed.






TALAPRO-2 is a two-part, two-cohort, multicenter,







compelling combination data from TALAPRO-2, we believe



Working to Deliver a Potential

If approved, combination therapy has potential to become new
standard of care.
Oncology
2022 Stories


. Last accessed October 31, 2022.

. Last accessed October 31, 2022.



*Pzer and Astellas jointly commercialize XTANDI in the United States, and Astellas has responsibility for manufacturing and all additional
regulatory lings globally, as well as commercializing XTANDI outside the United States.
ESG
Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
16
Precision medicine has transformed cancer care in recent




That’s because of the blood-brain barrier, which evolved
to block pathogens and toxins from entering the brain and


®


®
, is a third-generation medicine developed



barrier.
1

have brain metastases—cancer that has spread to the brain,

diagnosis.
2







targeting therapies.



3



®

4

metastases that could be measured saw their brain tumors



Out of 112
patients who did not have brain metastases when enrolled in

brain metastases.
 in the

didn’t stop there. We kept pushing the envelope.



advanced, biomarker-driven lung cancers.

®


Advanced ALK+ non-small cell lung cancer patients can now access
next-generation precision medicine earlier in treatment paradigm.
Oncology
2022 Stories
Precision medicine for lung cancer takes individual biomarkers into










ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review


take a substantial toll on children living with the condition and
their families.
1



1


1,2

provided, the better a child’s chances will be to achieve near-
normal height.
1



3


an emotional toll on parents and caregivers.

In fact, it’s



4

disease management burden and to increase treatment
adherence for children, their caregivers, loved ones, and
healthcare providers.


®
(somatrogon), a


secretion of growth hormone.


patients, their caregivers and healthcare providers with a




children living with this rare disease and their families, and for









to deliver this treatment, addressing unmet needs for the

disease.

see the full prescribing information here.


Once-weekly treatment reduces the frequency of required injections
for pediatric patients with GHD in the EU.
Rare Disease
2022 Stories


healthcare professionals.


. Accessed











ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review


from its Phase 3 clinical trial showing that its investigational
pentavalent meningococcal vaccine (MenABCWY)


meningococcal disease: serogroups A, B, C, W and Y.)


meningococcal vaccination according to Centers for Disease
Control and Prevention (CDC) guidance. However, less than a

meningitidis group B (MenB) vaccine, and fewer complete


serogroups A, B, C, W, and Y.
1,2
Routine use of a MenABCWY
vaccine could help improve meningococcal vaccination rates






and improve vaccine coverage. Our goal is to help ensure as

against this devastating disease," said Annaliesa Anderson,





this disease.
Advancing a Potential Meningococcal

Study results announced potentially support pentavalent
meningococcal vaccine candidate (MenABCWY) in adolescents.
Vaccines
2022 Stories
Meningococcal disease, while uncommon, has the potential to turn fatal
within 24 hours, so it is important to be protected against all serogroups.




Available at: 
ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
19



®
.









1,2


world.
3





to our ongoing commitment to help protect patients against





portfolio.
Helping Protect Patients Against
Pneumococcal Pneumonia
EMA approves Pzer's 20-valent pneumococcal conjugate vaccine in
individuals 18 years of age and older.
Vaccines
2022 Stories




European Centre for Disease Prevention and Control. Invasive pneumococcal disease. 
ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
20



1





2
The burden of this infectious disease is evident, but there




1


• announced








• announced positive top-line data

(MATernal ISSE


after birth.
3
• announced top-line data from the
RE
iNOlder adults IR

4
• 



for 

of pregnant women.







contagious nature of this infectious disease. If approved, our


3,4
We look forward to







Pzer’s advancement of a novel vaccine candidate.
Vaccines
2022 Stories







. Published 2022. Accessed October 26, 2022.


. Published 2022. Accessed December 12, 2022.

. Published 2022. Accessed December 12, 2022.

. Published 2022. Accessed October 26, 2022.

.
Published 2022. Accessed October 26, 2022.

. Published 2022, Accessed December 12, 2022
ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
21


advances, new cultural phenomena to global crises. One


®



since launch.
1,2







potential exposure to the TBE virus (TBEV).
The burden of TBE


3
It can lead to serious and
complicated long-term consequences, including cognitive

3,4


Therefore, it’s important to help
protect against TBE if spending time outdoors in an area
where there is a risk of being infected with the TBE virus.
These areas where there is a risk of TBE are increasing as
geographical reach of TBE is expanding.
To date, TBE has
been reported in more than 36 countries, from across Western


tick.
Providing a new option for protection





• Persons who are moving or traveling to a TBE-endemic
area and will have extensive exposure to ticks based on

• Persons traveling or moving to a TBE-endemic area who


to vaccinate should be based on an assessment of their

medical outcome, and personal perception and tolerance
of risk)
• 
virus (TBEV)

commitment to patients, helping ensure that a vaccine with

groups of at-risk individuals. This vote is important as it
provides clear guidance for healthcare providers on when a
TBE vaccine should be recommended to prevent infection,
supporting conversations between patients and healthcare
providers about whether vaccination is the right option for


As the world opens up again in the wake of COVID–19, this

are traveling or moving abroad to TBE-endemic areas in


ACIP recommendation provides new option for protection against
tick-borne encephalitis (TBE) for U.S. travelers
Vaccines
2022 Stories
Ticks live near the ground in long grass and can be found in parks and
gardens, as well as forests and meadows, both within or outside cities.
* ACIP recommendations are provisional until published in the Morbidity and Mortality Weekly Report (MMWR).
ESG
Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
22
their families, or those at risk of virus exposure through

themselves.
Ensuring that broader populations have the option to help


helping address tick-borne diseases.
2022 Stories


®
doses




ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
23





roles in our bodies, including helping to prevent infections


scientists around the globe excited about its potential future
applications.





we’ve advanced our work and collaborated with new partners


COVID–19.




progress.
Inuenza or Flu








might circulate and match the vaccines to the predicted


could result in better matches to circulating strains. This



Shingles



based vaccine for the prevention of shingles. We plan to start
human studies for this vaccine candidate in 2023.
Rare genetic diseases
We’ve established a research collaboration with Beam

new approach to gene editing, which is a form of gene



diseases—providing a potential one-time treatment for these
debilitating conditions. Our work is focused on rare genetic


working to address emerging variants of concern with the

countries across the world. Along with our collaboration



provide protection against these two infections with one
vaccine.



Transform Medicine
Building on the successful application of mRNA for COVID–19, our scientists
are exploring the use of mRNA technology in infectious disease and beyond.
Vaccines
2022 Stories

in infectious diseases and rare genetic diseases.
ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
24
The COVID–19 pandemic has been a stark reminder of

diseases. It has also worsened drug-resistant infections and
reinforced the need to invest in responsible antimicrobial use,
diagnostics, surveillance, and research and development to

antimicrobial resistance (AMR).
1,2


to rise unchecked, minor infections could become life-
threatening, serious infections could become impossible to


3,4



4
As a global anti-infective leader, we’re committed to tackling


Benchmark report, which highlighted our innovative policies
to improve access to our medicines and our leadership in
antimicrobial stewardship.

approach to the responsible use of antimicrobials—is
foundational to help curb AMR.


announced a collaboration with BD (Becton, Dickinson and

diagnostics in advancing antimicrobial stewardship practices
around the world.
6
Antimicrobial surveillance—the monitoring of changes in
populations of microbes to help understand patterns of


to better adapt antimicrobial stewardship programs to help
combat the spread of resistant pathogens.


surveillance data from our pioneering Antimicrobial Testing

Vivli’s AMR
Register will allow researchers, national governments, and


antimicrobial-resistant pathogens.
A robust pipeline of new antimicrobials is essential to
restoring the balance against increasing rates of AMR.








critical.


reimbursement model for antimicrobials.


model for antibiotics.

Antimicrobial surveillance—the monitoring of changes in populations of
microbes to help understand patterns of resistance to anti-infectives—is

Breakthroughs in the Fight Against
Antimicrobial Resistance
Our industry-leading initiatives to address this growing threat to
global health.
Anti-infectives
2022 Stories
ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review

reimbursement based on number of prescriptions and
instead focus on the value antibiotics bring to the public. This
encourages the appropriate use of existing antibiotics and

our arsenal against AMR.
This pilot could help to inspire change on a global scale. It’s
hoped that this model will set a precedent for governments

reimbursement models to attract much-needed investment in
antimicrobial research and development.





Access to Medicine Foundation. Antimicrobial resistance benchmark 2021. Available at 






.
2022 Stories
ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
26







clinical trials through equitable access and practices.








resulted in underrepresentation in clinical trials, including

Building trust and increasing awareness in diverse



voices in local pharmacies, hospitals, and religious institutions.


(HEAL) sessions to advance education around clinical trials

important as, in addition to historic underrepresentation in
breast cancer clinical trials,
1
Black women are often diagnosed
at a later stage and have a worse prognosis compared to white
women.
2
During these sessions, we focus on shedding light

access to breast cancer clinical trials, building trust and
enhancing relationships between cancer patients and their

improve access to trials, with the intent that this knowledge
will be shared across other treatment areas.




women with breast cancer, who are at a higher risk of disease

lifesaving. Our goal—through this partnership and others
like it—is to provide communities with the knowledge to
feel more educated and supported to participate in clinical


Clinical Trial Experience.
Although there is still work to be done, we have made
important progress in raising awareness, building trust,
and increasing access to clinical trials for even more people.

choose to participate in clinical trials, and we’re committed





patients and their families.


Clinical trials can advance medical breakthroughs, and so does
supporting equal access to clinical trials.
R&D
2022 Stories






ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review








However, long before the pandemic—over the course of the

development approach, revving up our engine of innovation
and making profound changes across multiple dimensions
to empower our scientists for critical decision-making. This
important evolution laid the foundation for responding with


• 
to approval development timeline for new medicines and

2022. We have ambitious goals to reduce timelines even
further so we can get medicines to patients even faster.
• 


2010 performance.
• 


1
• We’re proud of our achievement to date and intent to

enabling us to continue to deliver breakthroughs to
patients.






development timelines of these innovations is the real


Lightspeed includes searching for opportunities that upend
the standard approach to clinical development in areas with

through our science, capabilities, and thoughtful risk-taking.
Lightspeed is how we instill a pioneering spirit across our
teams so that we can keep pushing innovative thinking further
and move at the speed of science.
Leveraging lessons learned from the COVID–19 pandemic,




are certain elements that are at the core of the lightspeed

pipeline:
• Parallel testing.

test them in parallel studies so that the candidate with the

Parallel instead of sequential testing is perhaps one of the

• Expert dose selection. It is important that our vaccines



• Streamlined governance for rapid decision-making. A


time.
• Investment at risk.


transformation over the past decade, which can be seen through the
COVID–19 vaccine development.

with Lightspeed
Through focused eorts since 2010, Pzer transformed R&D output to
achieve leading success rates among industry leaders.
1
R&D
2022 Stories
ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review




Vaccine.
• Faster regulatory collaboration. We have witnessed

the pandemic, which has opened doors to greater digital













accelerate the development of our Phase 3 vaccine candidate

for both adults aged 60 and older and pregnant people to





The Pharmaceutical Benchmarking Forum
2022 Stories
Lightspeed is how we instill a pioneering spirit across our teams so that
we can keep pushing innovative thinking further and move at the speed
of science.
ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
29
Achieving breakthroughs in healt hcare requires constant
attention to ensure care evolves alongside the people who


to tackle them, we must coordinate tools and minds around
the world, including from outside our own walls. Too often,
innovations with the potential to change lives face roadblocks

not have access to the resources that can help them live up
to their potential. Our decades-long expertise in investment
and acquisition has focused on breakthrough products


more patients in need can access them as we grow.

innovation and product evolution, including preparation for
potential approvals and product launches, and support for



but also through various business development activities.


opportunities and transactions that have the potential to
strengthen our business and our capabilities. We assess our

of our regular, ongoing portfolio review process and also
continue to consider business development activities that will



at all stages of clinical and technological development and



investigating new therapies for neurological conditions, and





treatment and prevention of episodic migraine in adults,
rimegepant is part of a portfolio of promising calcitonin


Biohaven is part of our long-term work in pain and women’s
health, and continued momentum from a 2021 strategic




to rimegepant’s global success has helped bring an innovative
new treatment option to the millions of patients around the
world who live with migraine.

that has the potential to address the full spectrum of critical






will help accelerate innovation as we aim to bring potential

as possible.


products and programs across industries, sectors and
stakeholders. Our sustained success in supporting products
through partnership and acquisition addresses some of the


vaccines and antimicrobial resistance. With the expertise,
capabilities and reach of an international biopharmaceutical


of innovation through cutting-edge science and business
reimagination.
Partnerships will support ongoing exploration into innovative treatment
options for patients
A Team-First Approach to Patient Health
Investing strategically to address unmet needs and further serve
patients around the world.
Commercial
2022 Stories
ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
30






ingredients.
1




medicines: 
being done to stop them.
Organizations Tracking the Prevalence of Fake Meds
With counterfeit drugs, the packaging and design of the





Administration (FDA).
1




products. For example, one partnership between the FDA

and intercept counterfeit drugs coming from overseas. The

counterfeiting initiatives, such as guidance about imprinting


2



worldwide, from the Americas and Africa to Europe and Asia.
3
Of all reported counterfeits worldwide, malaria and antibiotic


3
One public health expert experienced fake



acetaminophen.
4
Combating Counterfeits Through Technology
and Partnerships

and putting an end to counterfeits. As a participant in the
Fight the Fakes
raise awareness and share the experience of individuals and

on-the-ground change, Fight the Fakes has hosted an annual
campaign.

anti-counterfeiting laboratories. In these labs, teams

Counterfeit Prescription Drugs:


Commercial
2022 Stories

putting an end to counterfeits.
In an expensive healthcare system, everybody wants more aordable
medicine, but at what physical or emotional cost?
ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
31



and respond to reports of counterfeits.
Through these partnerships and using advanced lab

has helped prevent over 302 million counterfeit doses from
reaching patients since 2004.
What You Can Do to Stop Counterfeit Drugs

looking for a good discount on their medications. But there

asking for a discount card, requesting generics, or using mail-


online drugstores that feature prices that seem too good to

answer questions.
1
look for a



provides .



other health problems. You can also report the suspected
counterfeit operation
6



2022 Stories










. Last

ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
32





and are committed to contributing to ongoing humanitarian


access to our medicines and vaccines for patients and have


To date, we have committed to donating $30 million through

people. This includes grants derived from 
to halt its investments in Russia and donate the equivalent
 to causes that provide

The Foundation has approved grants for 12 non-governmental



services, shelter, education for children, and other pressing








life-saving medicines through targeted product donations


help healthcare providers and relief workers treat patients in



we are one of the
largest donors to Direct Relief

tablets and ritonavir tablets).
Direct Relief:





Pzer stands in opposition to the Russian war in Ukraine and is
committed to contributing to humanitarian eorts.
Pzer Global Supply
2022 Stories




ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
33
needed to address this unfolding humanitarian crisis—an
infusion of much needed health essentials for the millions of
families who have had their lives upended while the health

them much more vulnerable and facing an uncertain future,"
said Thomas Tighe, Direct Relief President and CEO.
Pzer Ukraine Country Manager:





colleagues from the surrounding countries and all around


Humanitarian Disaster Campaign—which thanks to matching


individuals, through to whole cross-functional teams working
round clock to support and protect colleagues on the ground


critical. During the pandemic, I thought I could not be more

this time makes me even more proud. The millions of product
donations arranged and the $30 million of humanitarian



2022 Stories
PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of adults and pediatric
patients (12 years of age and older weighing at least 40 kg) with a current diagnosis of mild-to-moderate COVID-19 and who are at high risk for
progression to severe COVID-19, including hospitalization or death.
The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the
emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless
the declaration is terminated or authorization revoked sooner.
* The Pzer Foundation is a charitable organization established by Pzer Inc. It is a separate legal entity from Pzer Inc. with distinct legal
restrictions.
ESG
Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
34



gap in our world that too often determines who can access




that led us to launch An Accord for a Healthier World, a new

Through this groundbreaking initiative, launched at the



announce we will work towards sustained, equitable access


vulnerable to healthcare inequalities. Alongside governments


limit or prevent equitable access. We are focused on working

medicines and vaccines as well as strengthening the resources,
capabilities and platforms that can enable quicker and more


provide all its patented medicines and vaccines available in the



put forth the call to action to global health leaders around


medicines and vaccines can reach those who need them.





through the Accord, receiving nine medicines and vaccines
that can help treat life-threatening infectious diseases,


to provide professional healthcare education and training,



An Accord for a Healthier World
Bringing industry, governments, and global health stakeholders
together to close the health equity gap.
Pzer Global Supply
2022 Stories
An Accord for a Healthier World: Doctor examines child
Rwanda, Ghana,
Malawi, Senegal
and Uganda


to commit to

and solutions

be leveraged for
faster enrollment
and access in all
45 countries.




middle-income countries that transitioned from low-

World Bank.
Geographic Scope
ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review









this feedback and our commitment to address unmet patient











will also be included in the Accord portfolio.
We will continue to call upon governments, global health









2022 Stories
Albert Bourla in Davos.
ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
36
PAXLOVID as a tool in the ght against COVID-19
As COVID-19 continues to evolve, PAXLOVID (nirmatrelvir
tablets and ritonavir tablets) has shown to be an important


progressing to severe disease.
1




2,3

reduce the ongoing impact are vital to managing the pandemic
over the long term and transforming it into a manageable,


PAXLOVID treatment courses in 2022,
4
and in December


The Committee for Medicinal





6
Pzer’s Commitment to Access

global health leaders to expand access to PAXLOVID. As of




and middle-income countries. This includes an agreement





An
Accord for a Healthier World’ to support worldwide access to


9
Because

and treatment with PAXLOVID requires a positive COVID-19



Collaborative, and Americares that is focused on rapid scale-
up of test and treat capabilities in under-resourced countries.
10








Patent Pool (MPP) to facilitate the production and distribution

low- and middle-income countries. MPP has sub-licensed to




11
The Future of PAXLOVID

the PAXLOVID clinical development program, continuing
to explore opportunities to evaluate its potential in
vulnerable populations, including children and those who
Taking PAXLOVID
®
(nirmatrelvir tablets and
ritonavir tablets) from the Lab to Patients to
Combat COVID–19
Pzer is working to enable broad access to PAXLOVID worldwide and
evaluate the treatment for more who may benet.
2022 Stories
COVID–19
Pharmacist explaining a prescription to the patient.
* This gure includes treatment courses distributed to customers as well as those stored and ready for distribution.
ESG
Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review



PAXLOVID for patients who are at high risk for progression to
severe illness from COVID-19 is under review.
As COVID-19 evolves,
12

the virus, advancing promising science with a multi-pronged

proud of the hard work of our colleagues that has contributed
to our progress in combatting the virus, and we remain

2022 Stories

The Lancet Global Health

(2021, December 14). Pfizer.

.
Pfizer
from .

from 



.

.

.

.



and
.
Packing PAXLOVID to be distributed.
PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of adults and pediatric
patients (12 years of age and older weighing at least 40 kg) with a current diagnosis of mild-to-moderate COVID-19 and who are at high risk for
progression to severe COVID-19, including hospitalization or death.
The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the
emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless
the declaration is terminated or authorization revoked sooner
ESG
Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review

At the start of 2022, the Omicron variant was causing the

1 2


use  of a booster dose of our original COVID–19



needed in the meantime. We would need to use our existing
tools to help protect people of all ages against this persistent
viral threat.
In March 2022, an additional (fourth) booster dose was

—to help protect those at
higher risk of developing severe COVID–19 disease.
In April 2022, the FDA 





 for this age group in June.





Vaccine Boosters: A Year in Review for
Our COVID–19 Vaccination
While Omicron-adapted vaccines were being developed, our original COVID–19
vaccine nds new life in booster doses and as rst-line protection for the very young.
COVID–19
2022 Stories
Manufacturing of COVID–19 vaccine booster



Emergency uses of the vaccines have not been approved or licensed by FDA but have been authorized by FDA under an Emergency Use Authorization
(EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals aged 6 months and older. The emergency uses are only authorized for the
duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of
the FD&C Act unless the declaration is terminated or authorization revoked sooner. 
ESG
Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
39
The emergence of the Omicron variant in late 2021 presented




1
we began
trial investigating new vaccine candidates

outpacing other variants circulating at the time.
2

results


based on these emerging subvariants and began pre-clinical
testing.




variants.
The Food and Drug Administration (FDA) and European


we submitted applications to the FDA and EMA based on the
clinical data we collected for our BA.1-adapted vaccine as well




and older. The  followed suit with two bivalent vaccines in








age.





Evolving with the Virus
While Omicron was surging around the world, we were retooling
our arsenal.
COVID–19
2022 Stories
Manufacturing of COVID–19 vaccine




Emergency uses of the vaccines have not been approved or licensed by FDA but have been authorized by FDA under an Emergency Use Authorization
(EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals aged 6 months and older. The emergency uses are only authorized for the
duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of
the FD&C Act unless the declaration is terminated or authorization revoked sooner.
ESG
Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
40
We have all seen images of refugees whose lives have been






refugees have the talent and skills we are looking to hire, in


Refugees and later expanded the program to refugees from







for the program. We hired more than 100 refugees in 2022 and
have also announced our expanded aspirational goal of hiring

addition, we committed to mentoring 300 refugees through








a champion of the program. An Afghan refugee herself, she
understands the importance of having access to opportunities





have shared positive feedback on the refugee hires’













came up with the idea and built the initiative from scratch.






Helping refugees rebuild their careers and homes as they contribute
their much-valued skills and experiences.
Values
2022 Stories

ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
41


advance shared goals and better support the needs of patients


to drive deep therapeutic and regional relationship models



social impact issues, creating meaningful resources and
programs that provide value to patients and more.
PatientView Corporate Reputation in Pharma Survey


companies, according to the PatientView Corporate Reputation


perceptions of pharma companies across nine indicators,





help improve patient outcomes.
Patients in Focus Week
In October, we hosted our second annual Patients in Focus


impact patients and advocates have on our work. Colleagues

communities and met with Patient Engagement Leads who

engagement.


advocates.






With Patients. For Patients: Our

Recent top PatientView recognition and Patients in Focus Week
activities demonstrate Pzer’s commitment to patients globally.
Values
2022 Stories
Patient centricity exists at Pzer
when we listen and learn from
the patient perspective, acting as
partners with accountability and
integrity to deliver outcomes that
matter most to patients and those
involved in their care.

patient group supporting cross-rare disease patients and their families,
during Patients in Focus




ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
42



we are involving patients from the earliest stage of research

and vaccines.
Throughout the week more than 40,000 colleagues, from






of connectedness, pride in their work, and a deeper

engagement.
2022 Stories

Week




ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
43


bring about real change in underserved communities, we must


2022 Essence Festival of Culture, the largest African American




Black women shared and bonded over important topics,
including personal development, wealth creation, civic

a part of the conversation.





We sponsored a panel discussion featuring global singer





continued the conversation with the festival participants




educational resources on COVID–19 and the importance of
vaccinations including boosters.


media conversations on COVID–19 vaccinations and encourage




were there to share their own unique experiences with
festivalgoers.




Black women who are at the center of making healthcare
decisions for themselves, their children, and their parents. We
listened to their stories and we learned. And we will continue







Black women who represent the communities we serve across


for. We should feel safe to connect with one another as human





Be where the community is. Listen. Learn. That's how we raise
awareness about the importance of vaccinations.
2022 Stories
Values
ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
44



attendees of the festival come to our booth, some in tears, to








2022 Stories
ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review



clinical development, manufacturing, distribution, and







game-changer because it meant that patients could take the
treatment at home rather than in a hospital setting, which

people around the world.





clinical trials.






extra doses per batch. With the predictive capabilities of AI,

patients around the world.
The last important step has been to ensure that patients in




the Center for Disease Control, validating that infection rates




disparities in treatment exist.



improve patient access to diagnosis and treatment. In the


pharmacists to prescribe treatments for eligible patients, with
certain limitations.

developing more breakthroughs like PAXLOVID, faster than
ever before but also increasing the potential for patients to


Medicines to Patients Faster
Digital innovation helps deliver COVID–19 oral treatment, PAXLOVID
®
(nirmatrelvir tablets and ritonavir tablets), to patients.
Digital
2022 Stories


PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of adults and pediatric
patients (12 years of age and older weighing at least 40 kg) with a current diagnosis of mild-to-moderate COVID-19 and who are at high risk for
progression to severe COVID-19, including hospitalization or death.
The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the
emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless
the declaration is terminated or authorization revoked sooner.
ESG
Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review
46


purpose: breakthroughs that change patients’ lives. This
includes providing digital health solutions that support




mobile app that aims to support patients who have been

®
(palbociclib) for the treatment of



education, tips, self-scheduled medication reminders, a
connection with their social support network, and other useful


pharmacist.
Digital companions such as Amba are designed to help
patients understand their medication and provide information




patient experience, and we also are monitoring the program







digital health.

Improve Patients’ Lives
Embracing AI-based technology to provide treatment support for
patients with breast cancer.
Digital
2022 Stories



ESG Performance About This ReviewA Year In Review 
Pzer 2022 Annual Review

Living Our Values
Our Environmental, Social, and Governance
performance helps us to deliver on our purpose
every day.
Learn more about our progress on our goals in
our .
Living Our Values
Performance About This ReviewA Year In Review 2022 Stories 
Pzer 2022 Annual Review


Living Our Values
Environment

we are committed to reducing our environmental footprint. Our
Breakthroughs that change patients’ lives—guides
our environmental priorities, with a focus on impact reduction,

our operations.
Governance
Ethical decision-making guides us as we work to achieve our purpose
of delivering Breakthroughs that change patients’ lives. Through




Social
Breakthroughs that change patients’ lives—is
rooted in achieving social good. We know that when we succeed, our

be the solution for illnesses from widespread infectious diseases to



inequities in health outcomes among populations. Our goal is to
leverage partnerships and programs to allow quick and widespread
access to our breakthrough medicines and vaccines across all corners
of the world.
here.
here.
Performance About This ReviewA Year In Review 2022 Stories 
Pzer 2022 Annual Review
49
2022 Progress and Highlights
1
Living Our Values
Net-Zero
Standard


expectations of the standard

Ranking among the largest
Pharma companies in the most


Leadership
Level
for our CDP Climate Change
Disclosure


Representation for




4 out of 12
members of the Board
of Directors are women
3 out of 12
members of the
Board of Directors are

30k

factored into their compensation



in a row
“World’s Most Ethical Companies” and
“Ethisphere” names and marks are registered
trademarks of Ethisphere LLC.


and novel biologic applications


Breakthrough Therapies



emissions from 2019 baseline
1

Performance About This ReviewA Year In Review 2022 Stories 
Pzer 2022 Annual Review

Our approach to helping
address the issues
facing our planet and
its people is rooted
in our purpose—
Breakthroughs that
change patients’ lives
Dr. Albert Bourla

Living Our Values
Performance About This ReviewA Year In Review 2022 Stories 
Pzer 2022 Annual Review

Performance
Performance
2022 was a year in which we set all-time highs in
several nancial categories—including Revenue
and Adjusted Diluted EPS.
Learn more about our performance on our
Investor site.
About This ReviewA Year In Review 2022 Stories ESG Performance
Pzer 2022 Annual Review

Financial Performance

Reported net income
(a)

(a)

Cash dividends paid

(b)

(b)
Revenues
2022
$ 100,330
$ 31,372
$ 5.47
$ 37,717
$ 6.58
$ 29,267
$ 8,983
2021



$ 23,196
$ 4.06


2020


$ 1.63
$ 12,601
$ 2.24
$ 14,403

22/21
23
43
42
62
63
(10)
3
21/20

*
*


*
3
Millions, Except Per Share Data % Change
Indicates calculation not meaningful.
Net income attributable to Pzer Inc. common shareholders

Net income attributable to Pzer Inc. common shareholders


Non-GAAP Financial Measure: Adjusted Income section of Management’s



*
(a)
(b)
Performance
About This ReviewA Year In Review 2022 Stories ESG Performance
Pzer 2022 Annual Review

Top 10 Medicines and Vaccines
Performance


®1
$37,806 million


®
(apixaban)
2
$6,480 million


®
(palbociclib)
$5,120 million


®
(tofacitinib)
$1,796 million


®
(etanercept)
$1,003 million


®
(axitinib)
$1,003 million

PAXLOVID
®
(nirmatrelvir tablets and ritonavir tablets)
$18,933 million


®

3
$6,337 million


®

4
$2,447 million


®

$1,198 million

View the interactive graph on the Annual Review site.


sales of the above-mentioned vaccines.




1
2
3
4
About This ReviewA Year In Review 2022 Stories ESG Performance
Pzer 2022 Annual Review

About This Review
Section




download via link in the footer of this report.
This Annual Review contains forward-looking
statements about, among other topics, our


prospects, expectations for our product pipeline,
in-line products and product candidates, including


and other developing data, revenue contribution and




in-class or blockbuster status, strategic reviews,

repurchases, plans for and prospects of our
acquisitions, dispositions and other business-



COVID–19, including our COVID–19 products, our
expectations regarding the impact of COVID–19


to substantial risks and uncertainties. We cannot



assumptions prove inaccurate, actual results could


A further list and description of risks, uncertainties








website at 
www.
sec.gov. The forward-looking statements in this

this Annual Review, and we undertake no obligation

the result of new information or future events or
developments or otherwise.
Forward Looking Information



®


®

MYFEMBREE
®


®
is a registered trademark of Astellas Pharma Inc.
A Year In Review 2022 Stories ESG Performance About This Review
Pzer 2022 Annual Review


About This Review



exchanges.


P.O. Box 43006
Providence, RI 02940-3006



Internet: 
 


Registrar, Computershare, with inquiries
concerning shareholder accounts of
record and stock transfer matters, and for
information:
• Computershare Investment Program
• 
• Dividend reinvestment
• 
investments
• 
• Direct deposit of dividends
Stock Transfer Agent and Registrar
Pzer Public Policy Engagement for Global Public Health Additional Information
Shareholder Services and Programs





Review.














A Year In Review 2022 Stories ESG Performance About This Review
Pzer 2022 Annual Review
The product information provided in this





All rights reserved


